AxoGen (AXGN) Reports In-Line Q3 EPS

AxoGen (NASDAQ: AXGN) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $16 million versus the consensus estimate of $15.59 million.

Guidance:

Sees FY 2017 revenues up 40%

Sees FY 2018 revenues up 40%

For earnings history and earnings-related data on AxoGen (AXGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c